Research Teams - Stand Up To Cancer

Research Teams

Research  >  Research Portfolio  >  Research Teams  >  Research Teams

SU2C Lung Cancer Health Equity Research Team: Southeastern Consortium for Lung Cancer Health Equity

February 2022-January 2025

The Southeastern Consortium for Lung Cancer Health Equity (SC3), led by Dr. Robert A. Winn, assembles an outstanding interdisciplinary team of translational researchers positioned in the heart of the historical and current tobacco-producing region within the southeast. Collectively, SC3’s investigative team has unparalleled experience in lung cancer screening, translational research in lung cancer health disparities, community outreach and engagement, and recruiting and retaining racial and ethnic minorities and individuals from other medically underserved groups using evidence-based strategies. As NCI-designated cancer centers, all three centers report high enrollment of underserved minorities onto interventional trials and are committed to reducing the substantial disparities found in lung cancer outcomes in their collective Black/African American and rural communities.

Supported by:

ABOUT THIS TEAM’S RESEARCH

SU2C Lung Cancer Health Equity Research Team Southeastern Consortium for Lung Cancer Health Equity (SC3) will facilitate scientific collaborations among investigators at three National Cancer Institute-designated cancer centers: Massey Cancer Center (MCC) at Virginia Commonwealth University (VCU), Lineberger Comprehensive Cancer Center (LCCC) at the University of North Carolina-Chapel Hill (UNC), and Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC). The following leadership and investigative team also engages numerous community advocates are integral to the planning, implementation, and evaluation of this initiative.

MEET THE TEAM

The top scientists and researchers on the SU2C Lung Cancer Health Equity Research Team: Southeastern Consortium for Lung Cancer Health Equity (aka SC3) come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the SC3 Team Leader, Co-Leader, and Principal.

Team Members

Robert A. Winn, MD
Virginia Commonwealth University
Leader

Marvella E. Ford, PhD
Medical University of South Carolina
Co-leader, Community Engagement Leader

Louise Henderson, PhD
The University of North Carolina at Chapel Hill
Principal Investigator

Gerard Silvestri, MD
Medical University of South Carolina
Senior Investigator

Patrick Nana Sinkam, MD
Virginia Commonwealth University
Senior Investigator

Stephanie Wheeler, PhD
The University of North Carolina at Chapel Hill
Senior Investigator, Community Engagement Leader

Xianming Tan, PhD
The University of North Carolina at Chapel Hill
Biostatistician

Community Engagement Leader
Vanessa Sheppard, PhD
Virginia Commonwealth University

Katherine Tossas, PhD
Virginia Commonwealth University
Early Career Investigator

Marjory Charlot, MD
The University of North Carolina at Chapel Hill
Early Career Investigator

Santiago Lima, PhD
Virginia Commonwealth University
Early Career Investigator

Adam Fox, MD
Medical University of South Carolina
Early Career Investigator

Rose Velez, PhD
Virginia Commonwealth University
Project Manager

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and reviews by senior scientists every six months. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Click on the link below to see summaries of research results so far for the SU2C Lung Cancer Health Equity Research Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

This Team started its work in 2021, and publications will be posted when available.

Clinical Trials Referrals

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available; in fact, the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials aren’t completed because not enough people take part.

At StandUpToCancer.org/ClinicalTrials, you’ll find clinical trial information, answers to common questions, and a free clinical trial finder tool.

LEARN MORE

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Please validate the captcha
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.